Nuclear Receptors in Liver and Digestive Diseases

Nuclear Receptors in Liver and Digestive Diseases Navigation Menu

Print Version
AGENDA
Organizers: Ronald Evans, Saul Karpen, Joel Lavine, Ronald Margolis, Edward Doo, and Patricia Robuck
Day 1—Wednesday, November 7, 2007
8:00 a.m. – 8:15 a.m.	*Welcome* Griffin Rodgers, Director, NIDDK Workshop Goals Ronald Margolis, NIDDK
8:15 a.m. – 8:45 a.m.	Nuclear Receptors: Overview Ronald Evans, The Salk Institute for Biological Studies
8:45 a.m. – 10:05 a.m.	Session 1: Basic Biology of Nuclear Receptor Action Moderator: Bert O’Malley, Baylor College of Medicine
8:45 a.m.	Nuclear Receptors as Lipid Receptors David Mangelsdorf, The University of Texas (UT) Southwestern Medical Center
9:05 a.m.	Nuclear Co-Regulator Mechanisms in Disease Bert O’Malley, Baylor College of Medicine
9:25 a.m.	The Nuclear Receptor Signaling Atlas (NURSA) Ronald Margolis, NIDDK
9:45 a.m.	Discussion
10:05 a.m. – 10:25 a.m.	Break
10:25 a.m. – 11:45 a.m.	Session 2: Nuclear Receptor Physiology Moderator: David Mangelsdorf, UT Southwestern Medical Center
10:25 a.m.	Nuclear Receptors and Fibroblast Growth Factors in the Liver Steve Kliewer, UT Southwestern Medical Center
10:45 a.m.	Nuclear Receptor Regulation of Drug Disposition Chris Liddle, The University of Sydney, Westmead Hospital
11:05 a.m.	Bile Acid Signaling From Nuclear Receptors to G-Protein Coupled Receptors Johan Auwerx, Institut de Génétique et de Biologie Moléculaire et Cellulaire and Institut Clinique de la Souris, Strasbourg, France
11:25 a.m.	Discussion
11:45 a.m. – 1:00 p.m.	Lunch (on your own)
1:00 p.m. – 2:20 p.m.	Session 3: Integration of Nuclear Receptors and Homeostasis Moderator: Chris Glass, University of California (UC) at San Diego
1:00 p.m.	Nuclear Receptors and the Metabolic Syndrome Mitch Lazar, University of Pennsylvania
1:20 p.m.	Nuclear Receptors, Inflammation, and Metabolic Disease Chris Glass, UC at San Diego
1:40 p.m.	Metabolic Control Through the PGC-1/SIRT1 Transcriptional Complex Activity Pere Puigserver, Dana Farber Cancer Institute
2:00 p.m.	Discussion
2:20 p.m. – 2:40 p.m.	Break
2:40 p.m. – 3:10 p.m.	Clinical/Translational Challenges: Overview Saul Karpen, Baylor College of Medicine
3:10 p.m. – 4:50 p.m.	Session 4: *Hepatic Pathophysiology of Nuclear Receptors* Moderator: Michael Trauner, Medical University of Graz
3:10 p.m.	Molecular Regulation of Hepatic Fibrosis and the Role of Nuclear Receptors Scott Friedman, Mount Sinai School of Medicine
3:30 p.m.	Nuclear Receptors and Hepatotoxicity Wan Xie, University of Pittsburgh Medical College
3:50 p.m.	Cholestasis Michael Trauner, Medical University of Graz
4:10 p.m.	Late-Breaking Story: Identification of Heme as the Ligand for the Orphan Nuclear Receptors Rev-Erbα and Rev-Erbβ Thomas Burris, Pennington Biomedical Research Center
4:30 p.m.	Discussion
5:00 p.m. – 7:00 p.m.	Poster Session

Day 2—Thursday, November 8, 2007
8:00 a.m. – 9:40 a.m.	Session 5: *Disease States and Nuclear Receptors* Moderator: Joel Lavine, UC at San Diego
8:00 a.m.	Isolated Genetic Defects in Nuclear Receptors Krishna Chatterjee, Cambridge University
8:20 a.m.	Nuclear Receptors and Inflammatory Bowel Disease Frank Gonzalez, National Cancer Institute
8:40 a.m.	Non-Alcoholic Steatohepatitis Joel Lavine, UC at San Diego
9:00 a.m.	Gallstones Alan Hofmann, UC at San Diego
9:20 a.m.	Discussion
9:40 a.m. – 10:00 a.m.	Break
10:00 a.m. – 10:45 a.m.	Session 6: Late-Breaking Stories Moderator: Ronald Margolis, NIDDK
10:00 a.m.	Decreased Histone H3K9 Acetylation at Bile Acid Transporter Gene Promoters During Rat Liver Development and Obstructive Cholestasis Meena Ananthanarayanan, Mount Sinai Medical Center
10:15 a.m.	Farnesoid X Receptor, the Bile Acid Activated Nuclear Receptor, Attenuates Colon Cancer Development in Mice Grace Guo, University of Kansas Medical Center
10:30 a.m.	A Randomized, Placebo-controlled Trial of the PPARγ Ligand Rosiglitazone for Active Ulcerative Colitis Gary Wu, University of Pennsylvania
10:45 a.m. – 12:45 p.m.	Session 7: Translation Moderator: Erin Schuetz, St. Jude’s Hospital for Children
10:45 a.m.	Pharmacogenomics Erin Schuetz, St. Jude’s Hospital for Children
11:05 a.m.	The Design and Development of PPARdelta Ligands for the Treatment of Metabolic Syndrome Rich Heyman, Kalypsys, Inc.
11:25 a.m.	Diabetes, Drug Metabolism, and Vice Versa David Moore, Baylor College of Medicine
11:55 a.m.	Nuclear Receptors and NASH: Bench to Bedside Anna Mae Diehl, Duke University
12:15 p.m.	Discussion
12:45 p.m. – 1:00 p.m.	Open Discussion: Meeting Summary and Future Directions Panel: Meeting Organizers
1:00 p.m.	Adjourn